Calculus Of Going Hostile: Recent Lessons From The Field
Since Valeant/Pershing Square's high-profile offer for Allergan last year, there have been 12 unsolicited, public offers by strategic bidders for U.S.-listed companies (not including Mylan's recent $29 billion offer for Perrigo...To view the full article, register now.
Already a subscriber? Click here to view full article